Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: A trial of the ECOG-ACRIN Research Group (E4412) Meeting Abstract
| Authors: | Diefenbach, C. S.; Jegede, O.; Ansell, S. M.; Steidl, C.; Natkunam, Y.; Scott, D. W.; Mehta-Shah, N.; Amengual, J. E.; Forlenza, C. J.; Cole, P. D.; Bartlett, N. L.; David, K. A.; Advani, R. H.; Ambinder, R. F.; Thomas, S.; Ibrahimi, S.; Kahl, B. S. |
| Abstract Title: | Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: A trial of the ECOG-ACRIN Research Group (E4412) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 607 |
| Language: | English |
| ACCESSION: | WOS:001159306702120 |
| DOI: | 10.1182/blood-2023-184531 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
